Titan Pharmaceuticals Receives Feedback from FDA on Ropinirole Implant Development Program for PD


(March 7, 2016) - Titan Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has provided written feedback on the initial development plan for its proprietary ropinirole hydrochloride (HCL) implant for Parkinson's disease. The ropinirole implant is designed for the long-term, continuous delivery of ropinirole HCL for the treatment of signs and symptoms of Parkinson's disease. Read more…

Click for a printer friendly version

Back to top